Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Parkinson's disease (PD) is a neurodegenerative disorder of unknown aetiology with an
estimated incidence of 4.5-16/100,000 persons/year.
BIA 9-1067 is currently being developed by BIAL (Portela & Cª,S.A.) to be used in addition to
L-DOPA (Levodopa) /carbidopa or L-DOPA (Levodopa) / preparations in PD patients. Promising
results have been obtained for BIA 9-1067 in previous studies.